VEGFA and ovarian carcinoma: Treatment of ovarian cancer cell lines with the oral anti-hyperglycemic drugs rosiglitazone and metformin significantly decreased cell viability and VEGF expression, suggesting that targeting glucose metabolism in ovarian cancer may target tumour viability as well as the microvasculature.